VTE risk substantially higher in IBD patients with COVID-19

Key clinical point: Patients with inflammatory bowel disease (IBD) who contract SARS-CoV-2 infection are at a significantly higher risk for venous thromboembolism (VTE) and thus may benefit from thromboprophylaxis.

Major finding: SARS-CoV-2 infection was associated with 8.15-fold increased odds of VTE (P less than .001). The risk was however mitigated in patients on chronic anticoagulation (odds ratio [OR], 0.63; P = .66) and was even stronger among patients not previously on anticoagulation (OR, 14.31; P less than .001).

Study details: This was a case-crossover study of 482 patients with IBD who developed VTE between April 1, 2020, and March 30, 2021, in an established Veterans Affairs cohort.

Disclosures: The study was supported by grants from Pfizer Pharmaceuticals. J Lewis and N Khan declared receiving research funding and serving as a consultant or on data safety monitoring boards for various sources including Pfizer. Other authors had no disclosures.

Source: Mahmud N et al. Gastroenterology. 2021 Jun 14. doi: 10.1053/j.gastro.2021.06.012.

Key clinical point: Patients with inflammatory bowel disease (IBD) who contract SARS-CoV-2 infection are at a significantly higher risk for venous thromboembolism (VTE) and thus may benefit from thromboprophylaxis.

Major finding: SARS-CoV-2 infection was associated with 8.15-fold increased odds of VTE (P less than .001). The risk was however mitigated in patients on chronic anticoagulation (odds ratio [OR], 0.63; P = .66) and was even stronger among patients not previously on anticoagulation (OR, 14.31; P less than .001).

Study details: This was a case-crossover study of 482 patients with IBD who developed VTE between April 1, 2020, and March 30, 2021, in an established Veterans Affairs cohort.

Disclosures: The study was supported by grants from Pfizer Pharmaceuticals. J Lewis and N Khan declared receiving research funding and serving as a consultant or on data safety monitoring boards for various sources including Pfizer. Other authors had no disclosures.

Source: Mahmud N et al. Gastroenterology. 2021 Jun 14. doi: 10.1053/j.gastro.2021.06.012.

Key clinical point: Patients with inflammatory bowel disease (IBD) who contract SARS-CoV-2 infection are at a significantly higher risk for venous thromboembolism (VTE) and thus may benefit from thromboprophylaxis.

Major finding: SARS-CoV-2 infection was associated with 8.15-fold increased odds of VTE (P less than .001). The risk was however mitigated in patients on chronic anticoagulation (odds ratio [OR], 0.63; P = .66) and was even stronger among patients not previously on anticoagulation (OR, 14.31; P less than .001).

Study details: This was a case-crossover study of 482 patients with IBD who developed VTE between April 1, 2020, and March 30, 2021, in an established Veterans Affairs cohort.

Disclosures: The study was supported by grants from Pfizer Pharmaceuticals. J Lewis and N Khan declared receiving research funding and serving as a consultant or on data safety monitoring boards for various sources including Pfizer. Other authors had no disclosures.

Source: Mahmud N et al. Gastroenterology. 2021 Jun 14. doi: 10.1053/j.gastro.2021.06.012.